Introduction/Background The purpose of this study was to assess the prognostic significance of pathological features in the form of tumour size and lymphovascular space invasion (LVSI) in women with early stage endometrial cancer.
Methodology This is a retrospective observational study of all cases of early stage endometrial carcinoma (Stage I) diagnosed and treated at Tata Medical Centre, Kolkata- India from June 2011 to December 2018. The Demographic, clinicopathological and survival data was collected from the electronic hospital database and analysed using SPSS version 23. Survival analysis was done using Kaplan Meir method.
Results Among the women who were diagnosed and treated at Tata Medical Centre, 159 were staged as Stage I endometrial carcinoma. Of these were found to have lymphovascular invasion. Median age at diagnosis was 57 years (53–63). 103 patients (64%) belonged to Stage IA. Recurrence was noted in 11 patients and mortality in 6 (3.8%). The median tumour size was noted to be 3 cm. Positive LVSI was noted with grade 2 disease more frequently (48%, p=0.47), deeper myometrial invasion (72%, p=0.01), greater tumour size (p=0.35), recurrence (12% v/s 5.9%, p=0.239). The estimated 5 year recurrence free survival (RFS) is 84% in patients with positive LVSI compared to 88% in patients with negative LVSI (p=0.262). However no significant difference was noted in the 5 year overall survival (p=0.931). Other factor associated with poorer prognosis include age, increased risk of recurrence (p=0.311) but no association with survival. Tumour size was not associated with recurrence or survival.
Conclusion Lymphovascular invasion was associated with adverse pathological features for early stage endometrial cancer. When compared with patients negative for LVSI, recurrence was more frequently in patients with lymphovascular invasion, though not statistically significant. Tumour size did not contribute to prognosis in early stage endometrial carcinoma.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.